Biotech News

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio (GRI)GRI Bio2026-06-25 13:46 ESTClinical readout

Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)

GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and topline data on track for Q1 2025

LA JOLLA, CA, Aug. 14, 2024 (GLOBE...

Open original release

Related news

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio to Present at the 2024 European Respiratory Congress

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio Participates in Virtual Investor KOL Connect Segment

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis

GRIGRI Bio2026-06-25 13:46 EST

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

View all latest news

GRI Bio

GRI Bio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

GRIGRI Bio2026-06-26 09:30 EST

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRIGRI Bio2026-06-26 09:30 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GRIGRI Bio2026-06-26 09:30 EST

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GRIGRI Bio2026-06-26 09:30 EST

GRI Bio to Present at the 2024 European Respiratory Congress

GRIGRI Bio2026-06-26 09:30 EST

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States